(NASDAQ: CDMO) Avid Bioservices's forecast annual revenue growth rate of 15.86% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 53.11%, and while it is forecast to beat the US market's average forecast revenue growth rate of 7.5%.
Avid Bioservices's revenue in 2024 is $142,358,000.On average, 1 Wall Street analysts forecast CDMO's revenue for 2025 to be $10,462,397,712, with the lowest CDMO revenue forecast at $10,462,397,712, and the highest CDMO revenue forecast at $10,462,397,712.
In 2026, CDMO is forecast to generate $12,191,245,139 in revenue, with the lowest revenue forecast at $12,191,245,139 and the highest revenue forecast at $12,191,245,139.